Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin Maintenance in TP53WT Endometrial Cancer
NCT05797831Phase 3Recruiting
- Sponsor
- Kartos Therapeutics
- Start
- Jul 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of navtemadlin in endometrial cancer (EC), sponsored by Kartos Therapeutics. Started Jul 2023; status: recruiting.
02
Drugs
navtemadlin
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05797831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05797831.